ADC Therapeutics (ADCT) Gains from Investment Securities (2021 - 2023)
Historic Gains from Investment Securities for ADC Therapeutics (ADCT) over the last 3 years, with Q4 2023 value amounting to $279000.0.
- ADC Therapeutics' Gains from Investment Securities rose 10242.52% to $279000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$11.8 million, marking a year-over-year decrease of 292.94%. This contributed to the annual value of $1.2 million for FY2024, which is 33400.4% up from last year.
- ADC Therapeutics' Gains from Investment Securities amounted to $279000.0 in Q4 2023, which was up 10242.52% from -$157.0 million recorded in Q3 2023.
- In the past 5 years, ADC Therapeutics' Gains from Investment Securities registered a high of $908.0 million during Q2 2023, and its lowest value of -$157.0 million during Q3 2023.
- Its 3-year average for Gains from Investment Securities is $105.6 million, with a median of -$519.0 in 2021.
- As far as peak fluctuations go, ADC Therapeutics' Gains from Investment Securities plummeted by 2170556037.74% in 2022, and later skyrocketed by 10242.52% in 2023.
- Quarter analysis of 3 years shows ADC Therapeutics' Gains from Investment Securities stood at -$53.0 in 2021, then plummeted by 21705560.38% to -$11.5 million in 2022, then soared by 102.43% to $279000.0 in 2023.
- Its last three reported values are $279000.0 in Q4 2023, -$157.0 million for Q3 2023, and $908.0 million during Q2 2023.